Doctor profile · Federal record
Dr. Matthew Cotant, M.D.
Hematology & Oncology Physician (CMS: Hematology/Oncology) · Royal Oak, MI
- NPI 1003930215
- Accepts Medicare
- 25 yrs in practice
- Male
- Group practice
- No sanctions
Practice & contact
- Primary practice
-
3577 W 13 Mile RD, Suite 404
Royal Oak, MI 480736710
(248) 551-6900
fax (248) 551-6909
Credentials & registration
- NPI registered
- March 2007 — 19 yrs on file
- Profile last updated
- October 22, 2020
- Year of graduation
- 2001 — 25 yrs since
- Specialty taxonomy
- 207RH0003X — NUCC code
- State license (1)
- Michigan #4301077875
Federal sanctions & exclusions
No sanctions, exclusions or revocations on file
Checked against OIG LEIE on NPI 1003930215. Last verified May 11, 2026.Medicare procedures · 2023
Top services delivered
Total services
122,690
Distinct HCPCS
10
Medicare allowed
$1,418,848
| HCPCS | Description | Services | Patients | Avg allowed | |
|---|---|---|---|---|---|
Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | 21,930 | 30 | $1 | |
Q5110 |
Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram | 21,060 | 19 | $0 | |
J1439 |
Injection, ferric carboxymaltose, 1 mg | 12,750 | 15 | $1 | |
J9264 |
Injection, paclitaxel protein-bound particles, 1 mg | 10,200 | 15 | $13 | |
J9263 |
Injection, oxaliplatin, 0.5 mg | 9,700 | 13 | $0 | |
J9271 |
Injection, pembrolizumab, 1 mg | 8,800 | 17 | $54 | |
J1453 |
Injection, fosaprepitant, 1 mg | 7,950 | 24 | $0 | |
J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj | 5,760 | 11 | $47 | |
J0897 |
Injection, denosumab, 1 mg | 4,920 | 20 | $23 | |
J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units | 2,070 | 21 | $7 |
In context: peer comparison
Among 8 peers in Royal Oak Hematology & Oncology Physician, average services per provider: 1,850. This provider delivers 66× the peer median.Open Payments
Industry payments received
All-time total
$3,993
Transactions
114
Manufacturers
15
| Payer (manufacturer) | Industry | Txns | Amount |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | 33 | $1,382.41 | |
| Genentech USA, INC. | 15 | $291.52 | |
| Abbvie INC. | 9 | $159.61 | |
| Lilly USA, LLC | 7 | $155.63 | |
| Merck Sharp & Dohme LLC | 6 | $132.59 | |
| Janssen Biotech, INC. | 7 | $125.90 | |
| Bayer Healthcare Pharmaceuticals INC. | 5 | $112.32 | |
| Mirati Therapeutics, INC. | 6 | $109.80 | |
| BeiGene USA, INC. | 4 | $95.88 | |
| Gilead Sciences, INC. | 5 | $94.69 | |
| Emd Serono, INC. | 4 | $83.24 | |
| E.R. Squibb & Sons, L.L.C. | 4 | $80.75 | |
| Eisai INC. | 3 | $78.21 | |
| Daiichi Sankyo INC. | 3 | $68.45 | |
| AstraZeneca Pharmaceuticals Lp | 3 | $65.83 |
By nature of payment
Medicare Part D · 2023
Top prescriptions
Total claims
931
Patients
336
Total drug cost
$119,796
| Drug | Type | Claims | Patients | Total cost |
|---|---|---|---|---|
| Anastrozole | Generic | 195 | 60 | $12,277 |
| Eliquis (Apixaban) | Brand | 90 | 23 | $90,594 |
| Prochlorperazine Maleate | Generic | 89 | 75 | $3,679 |
| Prednisone | Generic | 85 | 37 | $528 |
| Omeprazole | Generic | 60 | 33 | $1,491 |
| Tamoxifen Citrate | Generic | 51 | 17 | $2,082 |
| Valacyclovir (Valacyclovir Hcl) | Brand | 50 | 12 | $2,027 |
| Potassium Chloride | Generic | 47 | 21 | $890 |
| Dexamethasone | Generic | 43 | 19 | $564 |
| Venlafaxine Hcl ER (Venlafaxine Hcl) | Brand | 43 | 13 | $1,171 |
Hospital affiliations
Frequently asked questions
What is Dr. Matthew Cotant's medical specialty?
Dr. Matthew Cotant practices Hematology & Oncology Physician in Royal Oak, MI.
Where does Dr. Matthew Cotant practice?
Dr. Matthew Cotant practices at 3577 W 13 Mile RD, Royal Oak, MI 480736710. Office phone: 2485516900.
What is Dr. Matthew Cotant's NPI?
Dr. Matthew Cotant's National Provider Identifier (NPI) is 1003930215, issued by NPPES.
Does Dr. Matthew Cotant accept Medicare assignment?
Yes. Dr. Matthew Cotant accepts Medicare assignment, meaning Medicare-allowed amounts are accepted as full payment for covered services.
What procedures does Dr. Matthew Cotant commonly perform?
Top Medicare-reported procedures in 2023: Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) (HCPCS Q0138); Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram (HCPCS Q5110); Injection, ferric carboxymaltose, 1 mg (HCPCS J1439). Source: CMS Medicare Physician & Other Practitioners file.